Tian Chen, Li Yueyang, Chen Zehui
Department of Hematology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, People's Republic of China.
Onco Targets Ther. 2020 Jun 10;13:5345-5352. doi: 10.2147/OTT.S248381. eCollection 2020.
Primary gastrointestinal non-Hodgkin lymphoma (PGIL) is a rare hematopoietic malignancy with limited data to guide management.
We analyzed the clinical characteristics and survival of 219 newly diagnosed PGIL patients.
Our single-center data showed that the incidence rate of primary gastric lymphoma (PGL) was higher than that of primary intestine lymphoma (PIL). Most PGIL was B-cell originated and DLBCL was the most common pathological type both in PGL and PIL group. Univariate and multivariate analysis showed that IPI score and pathology were independent prognostic factors. The overall survival (OS) and progression-free survival (PFS) of patients with MYC rearrangement were much shorter compared to patients without MYC rearrangement indicating that MYC translocation was related to decreased survival. Neither OS nor PFS differed between patients who received chemotherapy with or without surgery. However, patients who received surgery alone had a poor prognosis.
Chemotherapy is the front-line treatment for PGIL while surgery was conducted to relieve tumor-related complications or make diagnosis. MYC rearrangement predicted poor prognosis of PGIL patients.
原发性胃肠道非霍奇金淋巴瘤（PGIL）是一种罕见的造血系统恶性肿瘤，指导其治疗的数据有限。
我们分析了219例新诊断的PGIL患者的临床特征和生存情况。
我们的单中心数据显示，原发性胃淋巴瘤（PGL）的发病率高于原发性肠淋巴瘤（PIL）。大多数PGIL起源于B细胞，弥漫性大B细胞淋巴瘤（DLBCL）是PGL组和PIL组中最常见的病理类型。单因素和多因素分析表明，国际预后指数（IPI）评分和病理是独立的预后因素。与无MYC重排的患者相比，有MYC重排的患者的总生存期（OS）和无进展生存期（PFS）要短得多，这表明MYC易位与生存期缩短有关。接受化疗联合或不联合手术的患者的OS和PFS均无差异。然而，单纯接受手术的患者预后较差。
化疗是PGIL的一线治疗方法；而手术用于缓解肿瘤相关并发症或进行诊断。MYC重排预示着PGIL患者的预后不良。
